
Eisai and Arena’s Belviq has gained FDA approval, making it the first obesity drug to be approved in over ten …

An FDA panel has recommended Arena’s obesity drug lorcaserin, setting up a showdown with Vivus’ Qnexa. Qnexa was recommended by an FDA panel …

Vivus’ obesity drug Qnexa has been supported by an FDA panel, two years after it was knocked back by the …

Yet another investigational drug appears to have faltered on the rocky path to develop anti-obesity treatments. Takeda Pharmaceutical Company and …

